STA-9090
STA-9090 is a pharmaceutical drug with 10 clinical trials. Historical success rate of 77.8%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
8
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
70.0%
7 of 10 finished
30.0%
3 ended early
0
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
STA-9090 in Patients With Advanced Hepatocellular Cancer
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Clinical Trials (10)
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
STA-9090 in Patients With Advanced Hepatocellular Cancer
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Clinical and Translational Study of STA-9090
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10